Phase 3
Completed N=192
Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Hypertension
Source: ClinicalTrials.gov NCT01241240 ↗
Enrolled (actual)
192
Serious AEs
1.6%
Results posted
Sep 2014
Primary outcomePrimary: Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) at Week 12 — 24.62; 25.12; -10.03; -9.18 mmHg
Summary
This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) at Week 12 |
24.62; 25.12; -10.03; -9.18 | — |
| SECONDARY Change From Baseline in Mean Worse Eye IOP |
24.62; 25.12; -10.18; -8.90; -10.40; -9.06 | — |
| SECONDARY Mean Worse Eye IOP |
14.43; 16.23; 14.05; 16.08; 14.38; 15.96 | — |
Eligibility Criteria
Inclusion Criteria
- Ocular hypertension or primary open-angle glaucoma in each eye
- Requires treatment with IOP-lowering medication in both eyes
Exclusion Criteria
- Required chronic use of ocular medications during the study other than study medication
- Use of any corticosteroids within 30 days
- History of any prior eye surgery, except for uncomplicated eye surgery performed more than 6 months before the Screening visit
- Anticipated wearing of contact lenses during the study
Data sourced from ClinicalTrials.gov (NCT01241240). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.